Status: Recruiting
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Participants needed: 105
Trial details
Phase: Phase 1Age: 18-90Biological sex: AllType: InterventionalSponsor: Yale UniversityUpdated: May 31, 2025Locations: 1
Eligibility criteria
Male and Female subjects must be ≥18 and <90 years of age; [+8]